Redeye provides an initial comment on Scibase’s Q2 report, which came in slightly below our estimates. We are encouraged by the continued strong momentum in the US and note that the company is steadily positioning itself for broader adoption through reimbursement. By year-end, we anticipate initial reimbursement from smaller commercial insurance channels, with broader coverage to follow.
LÄS MER
